Skip to main content
. 2013 Mar 7;4(3):422–432. doi: 10.18632/oncotarget.917

Table 1. Relative expression of genes related to tumor growth.

Gene D-Trp6-LHRH DOX D-Trp6 + DOX AN-152
Angiopoietin 1 0.71 0.51 0.65 0.2
Insulin-like growth factor 1 0.33 0.5 0.22 0.08
Integrin, α4 (α4 subunit of VCAM-1 receptor) 0.25 0.33 0.59 0.46*
Integrin, αV (domain of vitronectin receptors) 0.25* 0.38 0.57 0.32*
Integrin, β5 (domain of vitronectin receptor) 1.14 1.3 0.84 0.46*
Mitogen-activated protein kinase 1 0.65* 1 0.19 0.22
Melanoma cell adhesion molecule 0.24* 0.57 0.19 0.06*
Matrix metalloproteinase 9 (gelatinase B) 0.34 0.73 0.5 0.2*
Metastasis associated 1 family, member 2 0.6 1.02 1.2 0.68*
Nuclear factor κB 0.85 1.13 0.11* 0.6*
Phosphoinositide-3-kinase, regulatory subunit 1α 0.49* 0.74 0.67 0.67*
Plasminogen activator (urokinase) 1.34 1.79* 0.8 0.6*
Platelet-derived growth factor α 0.83 1.52 4.09 0.36*
Serpin, clade B, member 5 (maspin) 0.16 0.14 17.67* 4.27
Tumor necrosis factor receptor superfamily, 10β 0.84 1.63 1.14 1.87*
V-raf-1 murine leukemia viral oncogene homolog 1 0.74 1.06 1.13 0.63*

In vivo glioblastoma specimens were evaluated by Cancer Pathway RT2 Profiler PCR Array system. Only genes with at least three-fold or statistically significant changes are represented. Four tumor samples from each group were analyzed. Relative expressions are compared to the control. *p < 0.05 vs. control. Abbreviations: DOX: doxorubicin, D-Trp6 + DOX: D-Trp6-LHRH + doxorubicin, VCAM: vascular cell adhesion molecule.